Again, applying my trend-following system to a single stock, this time Valeant Pharmaceuticals. Mr. Ackman clearly doesn't have a frayed-shirtcuff chartist on his staff who can identify trend reversals. For what it's worth, the system got long VRX again in early December; probably will wipe out the gain from earlier, but only time will tell.